UF Health Cancer Center – Application Guidelines for Cancer-Focused Bridge Grants 2017

ELIGIBILITY: This Bridge Grant Program is designed to support promising new research or competitive renewals that have nearly missed funding pay lines. Applicants must have a strong plan to use bridge funds to address critiques and a definitive timeline for resubmission. The research must have strong cancer relevance; clinical, basic and population research grants are all acceptable. Applications to federal funding agencies (NIH, DOD, AHRQ, etc) are eligible, however priority will be given to NCI R01, U01, or P01 applications.

Applicants must have received a review summary statement dated within the last 12 months. For NIH proposals, applications must have been ranked <30th percentile. For other agencies with descriptive adjectives for their evaluation criteria, applications must have received a rating of at least Excellent. Full-time UFHCC faculty members in Gainesville may apply. Newly recruited faculty with start-up packages are not eligible. If you are not yet a member and would like to apply, please submit a membership application.

AWARD AMOUNT & DURATION:
1. The maximum award for these grants is $75,000 direct cost for each award. No IDC is allowed.
2. The award is for a period of one year and all funds are expected to be expended during that term.

Applications should be submitted to Wendy Malorzo at wmalorzo@ufl.edu by February 15, 2017. Funds will be released in May 2017.

REQUIRED APPLICATION COMPONENTS MUST BE COMBINED INTO ONE PDF.

1-Cover Page: (Maximum: One page)
- Contact PI name and contact information;
- Federal Grant Application # & Project title;
- Names and departmental/institutional affiliations for all applicable UF and external personnel.

2-Previously reviewed complete federal application (include all sections)

3-Summary Statement: Include the summary statement/critique from the federal submission with priority score/percent score and critique. The statement must be dated after February 15, 2016.

4-Response to Critique: Provide plan to respond to the major criticisms in the review, including proposed timeline for resubmission. (Up to one page)

5-Current/Pending Other Support: PI only (project #, source, title, dates, direct costs, person months & major goals).

REVIEW CRITERIA: A Special Emphasis Panel of UF faculty will be assembled by the cancer center. In addition to alignment with UFHCC’s mission, evaluations will be based on percentile score, investigator, potential impact, response to critique/concerns, and plan to secure additional funding within the next 12 months.

AWARDEE REQUIREMENTS: Clinical trials must be registered and recorded in OnCore. UFHCC Shared Resources should be utilized when appropriate. It is expected that IRB/IACUC and other necessary approvals will be obtained within the first six months of the award. Funding will not be awarded until this requirement is met. IRB support can be provided by the Clinical Trials Office to expedite submissions.

Funds may be used for supplies and support personnel, excluding Principal Investigator and Co-Investigator salaries, and may not exceed the awarded amount. UFHCC does not pay indirect costs.

Awardees must reapply for the federal award within the next two funding cycles. If funding is secured and begins before the end of the bridge award period, UFHCC must be notified and may cease financial support of the project.

Awardees will submit a ½ page progress report at six months and the end of the funding period. Reports should include any new publications and whether a resubmission has occurred. Indicate if there are barriers to the research such as hiring personnel, accruing to clinical trials, IRB clearance. No cost extensions will be approved on a case by case basis, but are generally discouraged. Grantees will be required to report publications, grant submissions and funded grants resulting from this award for 5 years after the start of the award. Failure to make timely reports may impact eligibility for future UFHCC funding.

Awardees should use the following statement to acknowledge the funding source for your manuscript: “Research reported in this publication was supported by the University of Florida Health Cancer Center through the Florida Consortium of National Cancer Institute Centers Program at the University of Florida.”